Cervicitis screening: Difference between revisions
Prince Djan (talk | contribs) |
Prince Djan (talk | contribs) |
||
| Line 33: | Line 33: | ||
*Prior history of sexually transmitted infection | *Prior history of sexually transmitted infection | ||
*A new sexual partner | *A new sexual partner | ||
*More than one | *More than one sexual partner | ||
A | A sexual partner with concurrent partners | ||
*A sexual partner who has a sexually transmitted infection | *A sexual partner who has a sexually transmitted infection | ||
HIV infected women as follows: | HIV infected women as follows: | ||
Revision as of 14:03, 27 September 2016
|
Cervicitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cervicitis screening On the Web |
|
American Roentgen Ray Society Images of Cervicitis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Prince Tano Djan, BSc, MBChB [2]
Overview
Screening for the infectious causes of cervicitis is recommended according to the 2015 Sexually Transmitted Diseases Treatment Guidelines by the CDC.[1][2][3][4] Gonococcal and Chlamydial screening is recommended in sexually active women under 25 years of age, sexually active women aged 25 years and older if at increased risk, all pregnant women under 25 years of age and pregnant women aged 25 and older if at increased risk.
Screening
Screening for the infectious causes of cervicitis is recommended according to the 2015 Sexually Transmitted Diseases Treatment Guidelines by the CDC as follows:[1][2][3][4]
Chlamydia cervicitis
- Sexually active women under 25 years of age.
- Sexually active women aged 25 years and older if at increased risk.
- Retest approximately 3 months after treatment.
In pregnant women as follows:
- All pregnant women under 25 years of age.
- Pregnant women, aged 25 and older if at increased risk.
- Retest during the 3rd trimester for women under 25 years of age or at risk.
Individuals with HIV as follows:
- For sexually active individuals, screen at first HIV evaluation, and at least annually thereafter.
- More frequent screening might be appropriate depending on individual risk behaviors and the local epidemiology.
Gonococcal cervicitis
Screening is recommended in high risk people as follows:
Sexually active women under 25 years of age All pregnant women under 25 years of age and older women if at increased risk Sexually active women age 25 years and older if at increased risk as follows:
- Prior history of sexually transmitted infection
- A new sexual partner
- More than one sexual partner
A sexual partner with concurrent partners
- A sexual partner who has a sexually transmitted infection
HIV infected women as follows:
- For sexually active individuals, screen at first HIV evaluation, and at least annually
- More frequent screening for might be appropriate depending on individual risk behaviors and the local epidemiology
Herpes Cervicitis
Screening is recommended in pregnant women. Cesarean delivery is recommneded in pregnant women with active lesion.
Other nongonococcal infections
There is no specific screening modality for trichomonas vaginalis,[5] Mycoplasma genitalium and bacterial vaginosis.
References
- ↑ 1.0 1.1 "2015 Sexually Transmitted Diseases Treatment Guidelines (CDC)".
- ↑ 2.0 2.1 Workowski KA, Bolan GA. Sexually transmitted diseases treat- ment guidelines, 2015. MMWR Recomm Rep 2015;64:60–68.
- ↑ 3.0 3.1 Screening Recommendations Referenced in Treatment Guidelines and Original Recommendation Sources. CDC. http://www.cdc.gov/std/tg2015/screening-recommendations.htm. Accessed on January 6th, 2016
- ↑ 4.0 4.1 Screening recommendation for chlamydia. UPSTF. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening?ds=1&s=chlamydia(2014). Acessed on September 8, 2016
- ↑ Seña AC, Bachmann LH, Hobbs MM (2014). "Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations". Expert Rev Anti Infect Ther. 12 (6): 673–85. doi:10.1586/14787210.2014.887440. PMID 24555561.